Skip to main content
SpringerLink
Log in

A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

The authors describe a phase I trial of cisplatin plusdecitabine, a novel DNA-hypomethylating agent, in patients withadvanced solid tumors, which was followed by an early phase IIevaluation of the combination in patients with inoperablenon-small cell lung cancer (NSCLC). In the phase I trial,cisplatin was studied at a fixed dose of 33 mg/m2,while decitabine was escalated in four (I–IV) doseescalation levels (45, 67, 90 to 120 mg/m2,respectively) in consecutive groups of at least 3 patients perdose level. Decitabine was administered to the patients as atwo-hour intravenous infusion, while cisplatin was givenintravenously immediately after the end of decitabine infusion.Both agents were given on days 1–3 every 21 days.Twenty-one patients were included in the phase trial. Dose levelIV (120 mg/m2 decitabine) was considered the maximumtolerated dose (MTD), while the dose-limiting toxicities wereneutropenia, thrombocytopenia and mucositis. The recommendeddoses for phase II trials in good- and poor-risk patients were90 (level III) and 67 mg/m2 (level II), respectively.One short-lasting partial response was observed in a patient withcervical cancer, while two minor regression were documented ina patients with NSCLC and cervical cancer, respectively. Doselevel II was selected for the phase II trial in patients withinoperable NSCLC. Fourteen consecutive patients were included inthis part of the study. The median age of the patients was 57years (range, 39–75), male/female ratio of –11/3 anda median WHO performance status 1 (0–2). The stage ofdisease were IIIB (5) and IV (9). Prior irradiation to the chestwas given in one case. A total of 30 treatment courses wereevaluable for toxicity and response, with a median of 2 coursesper patient (1–4). Grade 3–4 neutropenia andthrombocytopenia were observed in about half of the cases.Mucositis, diarrhea, nausea and vomiting, and skin rash were alsoobserved in some patients. Three minor responses were documented,which lasted for 4, 16 and 36 weeks. Median survival of patientswas 15 weeks (4–38). In conclusion, the cisplatin plusdecitabine combination did not exhibit significant antitumoractivity in patients with NSCLC at the dose and schedule appliedin this trial to justify its further evaluation in this patientpopulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Health Statistics: Mortality figures in 1994; City of Porto Alegre, State of Rio Grande do Sul, Secretariat for Health and Environment, Ministry of Health of Brazil, Vol 20, 1996

  2. Hansen HH, Roth M: Lung Cancer. In Cancer Chemotherapy and Biological Response Modifiers Annual 12. HM Pinedo, DL Longo and BA Chabner, Eds. Elsevier Science Publishers BV: 449-459, 1991

  3. Thatcher N, Ranson M, Lee SM et al.: Chemotherapy in nonsmall cell lung cancer. Annals of Oncology 6: 83-95, 1995

    Google Scholar 

  4. Comis RL, Friedland DM: New chemotherapy agents in the treatment of advanced non-small cell lung cancer. Lung Cancer 12: 63-69, 1995

    Google Scholar 

  5. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data in individual patients from 52 randomized clinical trials. Br Med J 311: 899-909, 1995

    Google Scholar 

  6. Souquet PJ, Chauvin F, Boissel JP et al.: Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 342: 19-21, 1993

    Google Scholar 

  7. Grill R, Oxman AD, Julian JA: Chemotherapy for advanced non-small cell lung cancer: how much is enough? J Clin Oncol 11: 1866-1872, 1993

    Google Scholar 

  8. Fichtinger-Schepman AMJ, van der Veer JL, den Hartog JHL, Lohman PHM, Reedijk J: Adducts of the antitumor drug cis-diamminedichloroplatinum (II) with DNA. Formation, identification and quantitation. Biochemistry 24: 707-711, 1985

    Google Scholar 

  9. Reed E, Yuspa SH, Zwelling LA et al.: Quantitation of cis-diamminedichloroplatinum (II) (cisplatin)-DNA-intrastrands adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 77: 545-550, 1986

    Google Scholar 

  10. Momparler RL, Goodman J: In vitro cytotoxic and biochemical effects of 5-aza-2′-deoxycytidine. Cancer Res 37: 163-166, 1977

    Google Scholar 

  11. Lenzi R, Abbruzzese J, Hunt B, Jackson D, Frost P: Reversal of cisplatinum resistance by 5-aza-2′-aza-deoxycytidine (DAC) in human ovarian cell lines. Proc Am Assoc Cancer Res 33: 497, 1992 (Abstr #2865)

    Google Scholar 

  12. Frost P, Abbruzzese J, Hunt B, Lee D, Ellis M: Synergistic effect of cisplatinum in murine tumor cells pretreated with 2′-deoxy-5-azacytidine. In: 5-Aza-2′-deoxycytidine: Preclinical and clinical studies. Momparler RL, deVos D (eds), pp 29-34, PCH Publications, Haarlem, The Netherlands, 1990

    Google Scholar 

  13. Leyva A, Schwartsmann G, Boieje LMC et al.: Growth-inhibitory effects of 5-aza-2′-deoxycytidine in HL-60 promyelocytic leukemia cells resistant to differentiation induction. Biochem Biophys Res Commun 23: 595-597, 1987

    Google Scholar 

  14. Schwartsmann G, Pinedo HM, Leyva A: Resistance of HL-60 promyelocytic leukemia cells to induction of differentiation and its reversal by combination treatment. Eur J Cancer 23: 739-743, 1987

    Google Scholar 

  15. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP: 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64: 922-929, 1984

    Google Scholar 

  16. Gonzalez-Zulueta M, Bender CM, Pao MM, Zingg JM, Tsai YC, Arap W: Activation of a silent p16/CDKN2 tumor suppressor gene by 5-aza-2′-deoxycytidine restores growth control to human cancer cells. Proc Am Assoc Cancer Res 37: 420, 1996 (Abstr 2868)

    Google Scholar 

  17. Willemze R, Richel DJ, Arentsen-Honders MW, Colly LP: Preliminary results of 5-aza-2′-deoxycytidine (DAC) in patients with resistant and relapsed acute leukemia. In: 5-aza-2′-deoxycytidine: preclinical and clinical studies. Momparler RL, deVos D (eds). PCH Publications, Haarlem, The Netherlands, pp 183-190, 1990

    Google Scholar 

  18. Chabot GG, Monparlet RL: Pharmacokinetics of 5-aza-2′-deoxycytidine in animals and man: relevance to clinical trials. In: 5-aza-2′-deoxycytidine: preclinical and clinical trials. PCH Publications, Haarlem, The Netherlands, pp 105-116, 1990

    Google Scholar 

  19. Van Groeningen CJ, Leyva A, O'Brien A, Boeije L, Gall HE, Pinedo HM: Phase I and pharmacokinetic study of 5-Aza-2′-deoxycytidine in cancer patients. Cancer Res 46: 4831-4826, 1986

    Google Scholar 

  20. Dodion PF, Clavel M, ten Bokkel Huinink W, Robinson E, Renard J, Cavalli F: Phase I-II trials with 5-aza-2′-deoxycytidine conducted by the Early Clinical Trials Group of the EORTC. In: 5-aza-2′-deoxycytidine. Preclinical and clinical trials. PCH Publications, Haarlem, The Netherlands, pp 117-124, 1990

    Google Scholar 

  21. Willemze R, Richel DJ, Arentsen-Honders W, Colly LP: Preliminary results of 5-Aza-2′-deoxycytidine in patients with the Ara-C resistant and sensitive acute leukemia. In: Momparler RL, de Vos D (eds), 5-Aza-2′-deoxycytidine, preclinical and clinical studies. PCH Publications, Haarlem, The Netherlands, pp. 183-191, 1990

    Google Scholar 

  22. Schwartsmann G, Fernandes MS, Schaan MD et al.: Decytabine plus daunorubicin as first line treatment in patients with acute myeloid leukemia: Preliminary observations. Leukemia (Suppl 1) 11: 28-31, 1997

    Google Scholar 

  23. Schwartsmann G, Wanders J, Koier IJ et al.: EORTC New Drug Development Office coordinating and monitoring program for phase I and II trials with new anticancer agents. Eur J Cancer 27: 1182-1168, 1991

    Google Scholar 

  24. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-349, 1961

    Google Scholar 

  25. Miller AB, Hoogstraten B, Staquet M et al.: Reporting results of cancer therapy treatment. Cancer 47: 207-214, 1981

    Google Scholar 

  26. Lilenbaum RC, Green MR: Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J Clin Oncol 11: 1391-1402, 1993

    Google Scholar 

  27. Rapp E, Pater JK, Wellan A et al.: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633-641, 1988

    Google Scholar 

  28. Crino L, Scagliotti G, Marangolo M et al.: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer. A phase II study. J Clin Oncol 15: 297-303, 1997

    Google Scholar 

  29. Johnson DH, Paul DM, Hande KR et al.: Paclitaxel plus carboplatin in the treatment of advanced non-small cell cancer; A phase II trial. J Clin Oncol 14: 2054-2060, 1996

    Google Scholar 

  30. Zalcberg J, Millward M, Bishop J et al.: Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer. J Clin Oncol 16: 1948-1953, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. South-American Office for Anticancer Drug Development (SOAD), Porto Alegre, Brazil

    G. Schwartsmann, H. Schunemann, C.N.F. Gorini, A.F. Ferreira Filho, L DiLeone & D.R. Mans

  2. Hospital de Clinicas de Porto Alegre (HCPA-UFRGS), Brazil

    G. Schwartsmann & L DiLeone

  3. Hospital Luterano, (ULBRA), Brazil

    G. Schwartsmann, A.F. Ferreira Filho & D.R. Mans

  4. Hospital Nossa Senhora da Conceiçao, Porto Alegre, Brazil

    C.N.F. Gorini

  5. Hospital Policial, Montevideo, Uruguai

    C. Garbino

  6. Hospital de Clinicas, Montevideo, Uruguai

    G. Sabini & I. Muse

Authors
  1. G. Schwartsmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Schunemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C.N.F. Gorini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A.F. Ferreira Filho
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Garbino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Sabini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Muse
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L DiLeone
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D.R. Mans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwartsmann, G., Schunemann, H., Gorini, C. et al. A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer. Invest New Drugs 18, 83–91 (2000). https://doi.org/10.1023/A:1006388031954

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006388031954

Search

Navigation